Antares Pharma’s (ATRS) Buy Rating Reiterated at HC Wainwright
Antares Pharma (NASDAQ:ATRS)‘s stock had its “buy” rating reiterated by analysts at HC Wainwright in a research note issued to investors on Thursday. They currently have a $4.00 price objective on the specialty pharmaceutical company’s stock. HC Wainwright’s price objective points to a potential upside of 67.36% from the stock’s previous close.
A number of other equities analysts have also recently commented on ATRS. BidaskClub raised Antares Pharma from a “hold” rating to a “buy” rating in a report on Friday, December 22nd. Piper Jaffray Companies set a $3.00 price target on Antares Pharma and gave the stock a “buy” rating in a report on Monday, October 23rd. One equities research analyst has rated the stock with a sell rating, four have issued a buy rating and two have assigned a strong buy rating to the stock. The stock has an average rating of “Buy” and a consensus price target of $3.94.
Antares Pharma (NASDAQ:ATRS) traded up $0.04 during trading on Thursday, hitting $2.39. The stock had a trading volume of 3,180,000 shares, compared to its average volume of 1,220,000. The company has a debt-to-equity ratio of 0.69, a current ratio of 3.34 and a quick ratio of 2.89. Antares Pharma has a 12 month low of $1.58 and a 12 month high of $4.09. The firm has a market cap of $373.81, a PE ratio of -21.73 and a beta of 0.30.
About Antares Pharma
Antares Pharma, Inc (Antares) is a specialty pharmaceutical company that focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies. The Company develops and manufactures pressure-assisted injector devices, with and without needles, which allow patients to self-inject drugs.
Receive News & Ratings for Antares Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Antares Pharma and related companies with MarketBeat.com's FREE daily email newsletter.